產(chǎn)品展示
艾美捷 LKT Labs 阿法替尼解決方案
點擊次數(shù):0發(fā)布時間:2023/5/23 16:46:04
更新日期:2023/5/23 16:46:04
所 在 地:中國大陸
產(chǎn)品型號:
優(yōu)質(zhì)供應(yīng)
詳細(xì)內(nèi)容
艾美捷 LKT Labs 阿法替尼 基礎(chǔ)信息:
編號:A2077
cas:850140-72-6;439081-18-2
純度:≥98%
公式:C24H25ClFN5O3
配方重量:485.94
化學(xué)名稱:N-[4-[(3-氯-4-氟苯基)氨基]-7-[[(3S)-四氫-3-呋喃氧基]-6-喹唑啉基]-4(二甲氨基)-2-丁烯酰胺
IUPAC名稱:(2E)-N-4-[(3-氯-4-氟苯基)氨基]-7-[(3S)-四氫-3-呋喃氧基]-6-喹唑啉基}-4-(二甲氨基)-2-丁烯酰胺
同義詞:青苗 2992
熔點:130-142°C
外觀:淡黃色粉末
阿法替尼文獻(xiàn)參考:
Yap TA, Popat S. The role of afatinib in the management of non-small cell lung carcinoma. Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1529-39. PMID: 23985030.
Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013 Jun;54(6):936-43. PMID: 23578997.
Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. PMID: 22888144.
Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011 Jul;7(7):817-25. PMID: 21732753.